Click me
Transcribed

CJC-1295: details about a very popular hgh peptide

C]C-1295: - H,N. Arg-Ser-Leu-lle-Asp-Gin-Leu-Leu-Lys-Arg-Ala-Ser-Leu-Gin Tyr-dAla-Asp-Ala-lle-Phe-Thr-Gin-Ser-Tyr-Arg-Lys-Val-Leu-Ala dɛtails about a very popular hgh peptide CJC-1295 with DAC Summary: O A tetrasubstituted 30-amino acid peptide hormone created by Canadian company ConjuChem O Contains Dac witch stands for a drug affinity complex that increases half life from minutes to days O Provides a long term "growth hormone bleed" instead of GH pulsing CJC-1295 ModGRF SUBCUTANEOUS INJECTION DAC binds to Albumin in Plasma 7 to 8 Days Half-Life 7 Minutes CJC-1295 as a GHRH (Growth Hormone Releasing Hormone). O GHRH produced in the body is 44 amino acids long in chain structure. O CJC-1295 is a synthetic truncated form of GHRH but still has binding affinity to the GHRH receptors. O The DAC portion, is Drug Affinity Complex, which increases the half-life by bind the serum albumin and protecting the GHRH from degradation. O Mod GRF (CJC-1295 with no dac) has a half-life of roughly 7 minutes, where as CJC-1295 DAC lasts 7-8 days. O Promotes slow wave sleep (all GHRH products do). CJC-1295 Increased GH Concentration and Safety O A study was done in 2006 aiming to study the profile, effects and safety of CJC- 1295. Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependant increased in GH and IGF-1 levels in healthy adults and was safe and relatively well toler- ated, particularly at doses of 30 or 60 microg/kg. O There was evidence of a cumulative effect after multiple doses. This data supports the potential utility of CJC-1295 as a therapeutic agent. This shows safety and efficacy of CJC-1295. Up to 11 days of elevated IGF-1 from the increase in GH created with the DAC creating a half life of about a week, according to this study, without adverse reac- tion. O Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-lasting GH-releasing hormone analog. O The body naturally secretes GH in a pulsatile fashion, and this is considered impor- tant for most of the effects of GH to be properly mediated. The very short half-life of synthetic GHRH limits it's use therapeutically, though it does enhance GH pulses and IGF-1 levels. O Using the DAC version (CJC-1295) has shown enhanced growth hormone produc- tion in several species including rats and humans. CJC-1295 Normalizes Growth in Knockout Mice O Most children with growth hormone deficiency have a good growth response to GH-releasing hormone (GHRH), however the short half-life of this therapeutic agent limits its use. O In studies it has been shown that in mice the GHRH gene ablation (GHRH knock-out; GHRHKO) even doing injections twice daily of GHRH analog were unable to normalize growth. O CJC-1295 with DAC comes in to play by extending the half-life and duration of action. O Studies have shown that the half-life of CJC-1295 is in fact 8 days, once daily dosing is what it took to be most effective at normaliz- ing the growth of the GHRHKO mice studied, although all the animals did reach a higher body weight and length, even the mice treated every 72 hours. 2006 Journal of Clinical Endocrinology and Metabolism Study on CJC-1295 O Study shows that pulsatile release of GH remained intact with CJC-1295 use. O GHRH is very effective at raising GH levels in research subjects, but use is limited due to short half life. CJC-1295 has been shown to be effective to 8 days in duration. O At a dose of 60mcg/kg mean GH and IGF levels rose 40-50%, and at a dose of 90mcg/kg no additional benefit was found, meaning the optimal dose is less than 90mcg/kg and potentially less than 60mcg/kg. O Although growth hormone secretion was increased by nearly 50% there was no increase in pulse amplitude or frequency. The increase came entirely from a substantial elevation of trough levels with preserved pulsatility. O No serious adverse effects were observed in any of the subjects. Most commonly observed was an increase in heart rate that was dose dependent. All adverse effects were of short duration and not considered a problem by the subjects. O Adverse effects commonly seen with GH therapy were not shown in any of the subjects. O CJC-1295 therapy brought subjects up to high normal GH output for their ages, but did not exceed the normal range. References: [1] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. (2006). "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CC-1295, a long-acting analog of GH-releasing hormone, in healthy adults" Journal of Clinical Endocrinology and Metabolism. 91(3):799-805. [2] lonescu M, Frohman LA. (2006). "Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CC-1295, a long-acting GH-releasing hormone analog." Journal of Clinical Endocrinology and Metabolism. 91(121:4792-7. [3] Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. (2006). "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse" American Journal of Physiology, Endocrinology and Metabolism. 291(6):E1290-4. [4] Journal of Clinical Endocrinology and Metabolism. December 2006.

CJC-1295: details about a very popular hgh peptide

shared by Hardly on Apr 16
121 views
0 shares
0 comments
CJC-1295 - details about a very popular hgh peptide infographic. Learn about how CJC-1295 is a very effective hgh peptide. Full details, information and research studies about cjc-1295 brought to you...

Tags

None.

Source

Unknown. Add a source

Category

Health
Did you work on this visual? Claim credit!

Get a Quote

Embed Code

For hosted site:

Click the code to copy

For wordpress.com:

Click the code to copy
Customize size